In March 2026, CSPI’s Litigation Department took a stand for scientific integrity and public health, filing an amicus brief to challenge a Trump Administration Rule that threatens to deny tens of thousands of women access to FDA-approved contraceptives under their employer-sponsored health plans. The brief, which was filed on behalf of three former FDA officials, addresses the misleading and cherry-picked data cited by the Administration, as well as the rigorous science that goes into vetting FDA-approved contraceptives.
On April 2, 2025, CSPI’s Litigation Department and its co-counsel at the ACLU and Protect Democracy Project sued the National Institutes of Health (NIH) and the U.S. Department of Health and Human Services (HHS), challenging the new policy that led to the abrupt and unlawful cancellation of research grants and the halt of the application process for new grants.
CSPI’s Litigation Department is co-counsel in a class action lawsuit against Back to Nature alleging it misleads consumers about the whole grain content of its crackers.
This lawsuit seeks to compel the FDA to take a commonsense step to address the health and safety concerns related to the consumption of contaminated poppy seeds.
Quincy Bioscience, maker of 'brain support' supplement Prevagen, has been ordered to cease marketing its product for 'memory improvement.' Here's what to know.
